Patents by Inventor Birgitte P. S. Jacky

Birgitte P. S. Jacky has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Botulinum Neurotoxin Proteins and Methods to Engineer and Generate Same
    Publication number: 20230332126
    Abstract: Botulinum neurotoxin proteins and fragments thereof that bind and/or cleave a noncanonical substrate, e.g., non-neuronal SNARE proteins such as human SNAP-23 (hSNAP-23) and SNAP-29 (hSNAP-29), are described.
    Type: Application
    Filed: August 24, 2021
    Publication date: October 19, 2023
    Inventors: Gregory A. Weiss, Amy D. Brideau-Andersen, Rebekah P. Dyer, Lance E. Steward, Linh Q. Le, Gaetano Speciale, David C. Rupp, Birgitte P.S. Jacky, Madison H. Fletcher, Sudipta Majumdar
  • BOTULINUM NEUROTOXIN FOR TREATMENT OF DISORDERS ASSOCIATED WITH MELANOCYTE HYPERACTIVITY AND/OR EXCESS MELANIN
    Publication number: 20230302103
    Abstract: Methods for treating melanin-related afflictions of the skin, such as hyperpigmentation, are provided. The methods comprise administering a composition comprising BoNT/DC.
    Type: Application
    Filed: December 21, 2022
    Publication date: September 28, 2023
    Inventors: Birgitte P.S. Jacky, Shizazh Z. Malik, Joanne Wang, Yi Liu, Amy Brideau-Andersen, Lance E. Steward, Linh Q. Le, Edward C. Hsia
  • Botulinum toxin cell binding domain polypeptides and methods of use for skin rejuvenation
    Patent number: 11149262
    Abstract: A polypeptide having an amino acid sequence corresponding to a binding domain of a botulinum toxin is described. The polypeptide modulates expression of genes involved in, for example, collagen production and extra cellular matrix organization, and finds use, therefore in modulating skin quality attributes such as elasticity, firmness etc. Moreover, the polypeptide inhibits lipogenesis in specialized cells and finds use, therefore, in reducing skin oiliness, which is frequently observed in skin tissue afflicted with large pores and acne. Nucleic acids encoding the polypeptide, as well as vectors, host cells, and systems comprising the nucleic acids, are further described.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: October 19, 2021
    Assignee: Alleergan, Inc.
    Inventors: Birgitte P S Jacky, Amy Brideau-Andersen, Hui You, Shiazah Z. Malik, Donald E. Frail, Mitchell F. Brin
  • BOTULINUM NEUROTOXIN FOR TREATMENT OF DISORDERS ASSOCIATED WITH MELANOCYTE HYPERACTIVITY AND/OR EXCESS MELANIN
    Publication number: 20210162027
    Abstract: Methods for treating melanin-related afflictions of the skin, such as hyperpigmentation, are provided. The methods comprise administering a composition comprising BoNT/DC.
    Type: Application
    Filed: February 3, 2021
    Publication date: June 3, 2021
    Inventors: Birgitte P.S. Jacky, Shizazh Z. Malik, Joanne Wang, Yi Liu, Amy Brideau-Andersen, Lance E. Steward, Linh Q. Le, Edward C. Hsia
  • Botulinum neurotoxin for treatment of disorders associated with melanocyte hyperactivity and/or excess melanin
    Patent number: 10912823
    Abstract: Methods for treating melanin-related afflictions of the skin, such as hyperpigmentation, are provided. The methods comprise administering a composition comprising BoNT/DC.
    Type: Grant
    Filed: May 30, 2018
    Date of Patent: February 9, 2021
    Assignee: Allergan, Inc.
    Inventors: Birgitte P.S. Jacky, Shiazah Z. Malik, Joanne Wang, Yi Liu, Amy Brideau-Andersen, Lance E. Steward, Linh Q. Le, Edward C. Hsai
  • BOTULINUM NEUROTOXIN FOR TREATMENT OF DISORDERS ASSOCIATED WITH MELANOCYTE HYPERACTIVITY AND/OR EXCESS MELANIN
    Publication number: 20180344820
    Abstract: Methods for treating melanin-related afflictions of the skin, such as hyperpigmentation, are provided. The methods comprise administering a composition comprising BoNT/DC.
    Type: Application
    Filed: May 30, 2018
    Publication date: December 6, 2018
    Inventors: Birgitte P.S. Jacky, Shizazh Z. Malik, Joanne Wang, Yi Liu, Amy Brideau-Andersen, Lance E. Steward, Linh Q. Le, Edward C. Hsai
  • Cells Useful for Immuno-Based Botulinum Toxin Serotype A Activity Assays
    Publication number: 20170218334
    Abstract: The present specification discloses clonal cell lines susceptible to BoNT/A intoxication, methods of producing such clonal cell lines, and methods of detecting Botulinum toxin serotype A activity using such clonal cell lines.
    Type: Application
    Filed: April 17, 2017
    Publication date: August 3, 2017
    Inventors: Hong Zhu, Joanne Wang, Birgitte P.S. Jacky, D. Dianne Hodges, Ester Fernandez-Salas
  • Cells useful for immuno-based botulinum toxin serotype A activity assays
    Patent number: 9625447
    Abstract: The present specification discloses clonal cell lines susceptible to BoNT/A intoxication, methods of producing such clonal cell lines, and methods of detecting Botulinum toxin serotype A activity using such clonal cell lines.
    Type: Grant
    Filed: December 28, 2011
    Date of Patent: April 18, 2017
    Assignee: Allergan, Inc.
    Inventors: Hong Zhu, Joanne Wang, Birgitte P. S. Jacky, D. Dianne Hodges, Fernandez-Salas Ester
  • Cells useful for immuno-based botulinum toxin serotype a activity assays
    Patent number: 8691566
    Abstract: The present specification discloses clonal cell lines susceptible to BoNT/A intoxication, methods of producing such clonal cell lines, and methods of detecting Botulinum toxin serotype A activity using such clonal cell lines.
    Type: Grant
    Filed: December 28, 2011
    Date of Patent: April 8, 2014
    Inventors: Hong Zhu, Joanne Wang, Birgitte P. S. Jacky, D. Dianne Hodges, Fernandez-Salas Ester
  • Cells Useful for Immuno-Based Botulinum Toxin Serotype A Activity Assays
    Publication number: 20140093957
    Abstract: The present specification discloses clonal cell lines susceptible to BoNT/A intoxication, methods of producing such clonal cell lines, and methods of detecting Botulinum toxin serotype A activity using such clonal cell lines.
    Type: Application
    Filed: December 28, 2011
    Publication date: April 3, 2014
    Inventors: Hong Zhu, Joanne Wang, Birgitte P.S. Jacky, D. Dianne Hodges, Fernandez-Salas Ester
  • Cells useful for immuno-based botulinum toxin serotype A activity assays
    Patent number: 8663982
    Abstract: The present specification discloses clonal cell lines susceptible to BoNT/A intoxication, methods of producing such clonal cell lines, and methods of detecting Botulinum toxin serotype A activity using such clonal cell lines.
    Type: Grant
    Filed: December 28, 2011
    Date of Patent: March 4, 2014
    Assignee: Allergan, Inc.
    Inventors: Hong Zhu, Joanne Wang, Birgitte P. S. Jacky, D. Dianne Hodges, Fernandez-Salas Ester
  • Cells useful for immuno-based botulinum toxin serotype A activity assays
    Patent number: 8663983
    Abstract: The present specification discloses clonal cell lines susceptible to BoNT/A intoxication, methods of producing such clonal cell lines, and methods of detecting Botulinum toxin serotype A activity using such clonal cell lines.
    Type: Grant
    Filed: December 28, 2011
    Date of Patent: March 4, 2014
    Assignee: Allergan, Inc.
    Inventors: Hong Zhu, Joanne Wang, Birgitte P. S. Jacky, D. Dianne Hodges, Fernandez-Salas Ester
  • Cells useful for immuno-based botulinum toxin serotype A activity assays
    Patent number: 8603812
    Abstract: The present specification discloses clonal cell lines susceptible to BoNT/A intoxication, methods of producing such clonal cell lines, and methods of detecting Botulinum toxin serotype A activity using such clonal cell lines.
    Type: Grant
    Filed: December 28, 2011
    Date of Patent: December 10, 2013
    Assignee: Allergan, Inc.
    Inventors: Hong Zhu, Joanne Wang, Birgitte P. S. Jacky, D. Dianne Hodges, Fernandez-Salas Ester
  • Cells useful for immuno-based botulinum toxin serotype A activity assays
    Patent number: 8603813
    Abstract: The present specification discloses clonal cell lines susceptible to BoNT/A intoxication, methods of producing such clonal cell lines, and methods of detecting Botulinum toxin serotype A activity using such clonal cell lines.
    Type: Grant
    Filed: December 28, 2011
    Date of Patent: December 10, 2013
    Assignee: Allergan, Inc.
    Inventors: Hong Zhu, Joanne Wang, Birgitte P. S. Jacky, D. Dianne Hodges, Fernandez-Salas Ester
  • Cells Useful for Immuno-Based Botulinum Toxin Serotype A Activity Assays
    Publication number: 20130236963
    Abstract: The present specification discloses clonal cell lines susceptible to BoNT/A intoxication, methods of producing such clonal cell lines, and methods of detecting Botulinum toxin serotype A activity using such clonal cell lines.
    Type: Application
    Filed: December 28, 2011
    Publication date: September 12, 2013
    Inventors: Hong Zhu, Joanne Wang, Birgitte P.S. Jacky, D. Dianne Hodges, Fernandez-Salas Ester
  • METHODS OF TREATING CANCER USING OPIOD RETARGETED ENDOPEPIDASES
    Publication number: 20130230502
    Abstract: The present specification discloses TVEMPs, compositions comprising such TVEMPs and methods of treating cancer in a mammal using such TVEMP compositions.
    Type: Application
    Filed: November 20, 2012
    Publication date: September 5, 2013
    Applicant: ALLERGAN, INC.
    Inventors: Birgitte P.S. Jacky, Patton E. Garay, Yanira Molina, Dean G. Stathakis, Joseph Francis, Kei Roger Aoki, Ester Fernandez-Salas
  • Cells useful for immuno-based botulinum toxin serotype A activity assays
    Patent number: 8507271
    Abstract: The present specification discloses clonal cell lines susceptible to BoNT/A intoxication, methods of producing such clonal cell lines, and methods of detecting Botulinum toxin serotype A activity using such clonal cell lines.
    Type: Grant
    Filed: December 28, 2011
    Date of Patent: August 13, 2013
    Assignee: Allergan, Inc.
    Inventors: Hong Zhu, Joanne Wang, Birgitte P. S. Jacky, D. Dianne Hodges, Fernandez-Salas Ester
  • Cells useful for immuno-based botulinum toxin serotype A activity assays
    Patent number: 8501469
    Abstract: The present specification discloses clonal cell lines susceptible to BoNT/A intoxication, methods of producing such clonal cell lines, and methods of detecting Botulinum toxin serotype A activity using such clonal cell lines.
    Type: Grant
    Filed: December 28, 2011
    Date of Patent: August 6, 2013
    Assignee: Allergan, Inc.
    Inventors: Hong Zhu, Joanne Wang, Birgitte P. S. Jacky, D. Dianne Hodges, Fernandez-Salas Ester
  • Methods of Treating Cancer Using Growth Factor Retargeted Endopeptidases
    Publication number: 20130195838
    Abstract: The present specification discloses TVEMPs, compositions comprising such TVEMPs and methods of treating cancer in a mammal using such TVEMP compositions.
    Type: Application
    Filed: August 9, 2012
    Publication date: August 1, 2013
    Applicant: ALLERGAN, INC.
    Inventors: Birgitte P.S. JACKY, Patton E. Garay, Yanira Molina, Dean G. Stathakis, Joseph Francis, Kei Roger Aoki, Ester Fernandez-Salas, Lance E. Steward, Sanjiv Ghanshani, Terrence J. Hunt
  • Botulinum toxin screening assays
    Patent number: 8497081
    Abstract: Methods for detecting BoNT/A activity in a sample, methods for screening molecules able to compete with BoNT/A receptor binding, methods for reducing BoNT/A activity in a human and methods of marketing a neurotoxin capable of selectively binding to a FGFR2, a FGFR3, a SV2, or any combination thereof, to a governmental or regional regulatory authority.
    Type: Grant
    Filed: May 20, 2009
    Date of Patent: July 30, 2013
    Assignee: Allergan, Inc.
    Inventors: Ester Fernandez-Salas, Birgitte P. S. Jacky, Patton E. Garay, Kei Roger Aoki